tetano
Editor, Senior Moderator
MAbs
. Jan-Dec 2021;13(1):1930636.
doi: 10.1080/19420862.2021.1930636.
A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351
Chunyin Gu[SUP] 1 [/SUP], Xiaodan Cao[SUP] 1 [/SUP], Zongda Wang[SUP] 1 [/SUP], Xue Hu[SUP] 2 [/SUP], Yanfeng Yao[SUP] 3 [/SUP], Yiwu Zhou[SUP] 4 [/SUP], Peipei Liu[SUP] 1 [/SUP], Xiaowu Liu[SUP] 1 [/SUP], Ge Gao[SUP] 3 [/SUP], Xiao Hu[SUP] 2 [/SUP], Yecheng Zhang[SUP] 2 [/SUP], Zhen Chen[SUP] 2 [/SUP], Li Gao[SUP] 1 [/SUP], Yun Peng[SUP] 3 [/SUP], Fangfang Jia[SUP] 1 [/SUP], Chao Shan[SUP] 2 [/SUP], Li Yu[SUP] 1 [/SUP], Kunpeng Liu[SUP] 2 [/SUP], Nan Li[SUP] 1 [/SUP], Weiwei Guo[SUP] 2 [/SUP], Guoping Jiang[SUP] 1 [/SUP], Juan Min[SUP] 3 [/SUP], Jianjian Zhang[SUP] 1 [/SUP], Lu Yang[SUP] 1 [/SUP], Meng Shi[SUP] 1 [/SUP], Tianquan Hou[SUP] 1 [/SUP], Yanan Li[SUP] 1 [/SUP], Weichen Liang[SUP] 1 [/SUP], Guoqiao Lu[SUP] 1 [/SUP], Congyi Yang[SUP] 1 [/SUP], Yuting Wang[SUP] 1 [/SUP], Kaiwen Xia[SUP] 1 [/SUP], Zheng Xiao[SUP] 1 [/SUP], Jianhua Xue[SUP] 1 [/SUP], Xueyi Huang[SUP] 1 [/SUP], Xin Chen[SUP] 1 [/SUP], Haixia Ma[SUP] 3 [/SUP], Donglin Song[SUP] 3 [/SUP], Zhongzong Pan[SUP] 1 [/SUP], Xueping Wang[SUP] 1 [/SUP], Haibing Guo[SUP] 1 [/SUP], Hong Liang[SUP] 1 [/SUP], Zhiming Yuan[SUP] 3 [/SUP], Wuxiang Guan[SUP] 3 [/SUP], Su-Jun Deng[SUP] 1 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes coronavirus disease-2019 (COVID-19), interacts with the host cell receptor angiotensin-converting enzyme 2 (hACE2) via its spike 1 protein during infection. After the virus sequence was published, we identified two potent antibodies against the SARS-CoV-2 receptor binding domain (RBD) from antibody libraries using a phage-to-yeast (PtY) display platform in only 10 days. Our lead antibody JMB2002, now in a Phase 1 clinical trial (ChiCTR2100042150), showed broad-spectrum in vitro blocking activity against hACE2 binding to the RBD of multiple SARS-CoV-2 variants, including B.1.351 that was reportedly much more resistant to neutralization by convalescent plasma, vaccine sera and some clinical-stage neutralizing antibodies. Furthermore, JMB2002 has demonstrated complete prophylactic and potent therapeutic efficacy in a rhesus macaque disease model. Prophylactic and therapeutic countermeasure intervention of SARS-CoV-2 using JMB2002 would likely slow down the transmission of currently emerged SARS-CoV-2 variants and result in more efficient control of the COVID-19 pandemic.
Keywords: B.1.1.7; B.1.351; D614G; JMB2002; SARS-CoV-2; broad-spectrum; neutralizing antibody; phage-to-yeast; rhesus macaque disease model.
. Jan-Dec 2021;13(1):1930636.
doi: 10.1080/19420862.2021.1930636.
A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351
Chunyin Gu[SUP] 1 [/SUP], Xiaodan Cao[SUP] 1 [/SUP], Zongda Wang[SUP] 1 [/SUP], Xue Hu[SUP] 2 [/SUP], Yanfeng Yao[SUP] 3 [/SUP], Yiwu Zhou[SUP] 4 [/SUP], Peipei Liu[SUP] 1 [/SUP], Xiaowu Liu[SUP] 1 [/SUP], Ge Gao[SUP] 3 [/SUP], Xiao Hu[SUP] 2 [/SUP], Yecheng Zhang[SUP] 2 [/SUP], Zhen Chen[SUP] 2 [/SUP], Li Gao[SUP] 1 [/SUP], Yun Peng[SUP] 3 [/SUP], Fangfang Jia[SUP] 1 [/SUP], Chao Shan[SUP] 2 [/SUP], Li Yu[SUP] 1 [/SUP], Kunpeng Liu[SUP] 2 [/SUP], Nan Li[SUP] 1 [/SUP], Weiwei Guo[SUP] 2 [/SUP], Guoping Jiang[SUP] 1 [/SUP], Juan Min[SUP] 3 [/SUP], Jianjian Zhang[SUP] 1 [/SUP], Lu Yang[SUP] 1 [/SUP], Meng Shi[SUP] 1 [/SUP], Tianquan Hou[SUP] 1 [/SUP], Yanan Li[SUP] 1 [/SUP], Weichen Liang[SUP] 1 [/SUP], Guoqiao Lu[SUP] 1 [/SUP], Congyi Yang[SUP] 1 [/SUP], Yuting Wang[SUP] 1 [/SUP], Kaiwen Xia[SUP] 1 [/SUP], Zheng Xiao[SUP] 1 [/SUP], Jianhua Xue[SUP] 1 [/SUP], Xueyi Huang[SUP] 1 [/SUP], Xin Chen[SUP] 1 [/SUP], Haixia Ma[SUP] 3 [/SUP], Donglin Song[SUP] 3 [/SUP], Zhongzong Pan[SUP] 1 [/SUP], Xueping Wang[SUP] 1 [/SUP], Haibing Guo[SUP] 1 [/SUP], Hong Liang[SUP] 1 [/SUP], Zhiming Yuan[SUP] 3 [/SUP], Wuxiang Guan[SUP] 3 [/SUP], Su-Jun Deng[SUP] 1 [/SUP]
Affiliations
- PMID: 34097570
- DOI: 10.1080/19420862.2021.1930636
Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes coronavirus disease-2019 (COVID-19), interacts with the host cell receptor angiotensin-converting enzyme 2 (hACE2) via its spike 1 protein during infection. After the virus sequence was published, we identified two potent antibodies against the SARS-CoV-2 receptor binding domain (RBD) from antibody libraries using a phage-to-yeast (PtY) display platform in only 10 days. Our lead antibody JMB2002, now in a Phase 1 clinical trial (ChiCTR2100042150), showed broad-spectrum in vitro blocking activity against hACE2 binding to the RBD of multiple SARS-CoV-2 variants, including B.1.351 that was reportedly much more resistant to neutralization by convalescent plasma, vaccine sera and some clinical-stage neutralizing antibodies. Furthermore, JMB2002 has demonstrated complete prophylactic and potent therapeutic efficacy in a rhesus macaque disease model. Prophylactic and therapeutic countermeasure intervention of SARS-CoV-2 using JMB2002 would likely slow down the transmission of currently emerged SARS-CoV-2 variants and result in more efficient control of the COVID-19 pandemic.
Keywords: B.1.1.7; B.1.351; D614G; JMB2002; SARS-CoV-2; broad-spectrum; neutralizing antibody; phage-to-yeast; rhesus macaque disease model.